FDA panel finds Paxlovid benefit-risk is favorable for treatment of COVID-19 in those at high-risk of progresing to severe illness • Source: Shutterstock
Learn what's happening at the US FDA. On the go.
Derrick Gingery and the team bring you a weekly "Drug Fix".
